Immunic Inc
NASDAQ:IMUX
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
Immunic Inc
Operating Income
Immunic Inc
Operating Income Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Operating Income | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Immunic Inc
NASDAQ:IMUX
|
Operating Income
-$103.2m
|
CAGR 3-Years
-6%
|
CAGR 5-Years
-16%
|
CAGR 10-Years
-7%
|
|
|
BioNTech SE
NASDAQ:BNTX
|
Operating Income
-€215.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
CureVac NV
NASDAQ:CVAC
|
Operating Income
€177.7m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Immatics NV
NASDAQ:IMTX
|
Operating Income
-€182m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-21%
|
CAGR 10-Years
N/A
|
|
|
Biotest AG
XETRA:BIO
|
Operating Income
€11.9m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
-1%
|
CAGR 10-Years
-12%
|
|
|
Formycon AG
XETRA:FYB
|
Operating Income
-€30.5m
|
CAGR 3-Years
-20%
|
CAGR 5-Years
-36%
|
CAGR 10-Years
N/A
|
|
Immunic Inc
Glance View
Immunic, Inc. is a clinical-stage biopharmaceutical company, which develops a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases. The company is headquartered in New York City, New York and currently employs 55 full-time employees. The company went IPO on 2014-04-17. The firm is focused on developing oral therapies for the treatment of chronic inflammatory and autoimmune diseases. The firm is developing three small molecule products: IMU-838 is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function. The Company’s lead development program, IMU-838, is in Phase II clinical development for ulcerative colitis and relapsing-remitting multiple sclerosis, with an additional Phase II trial in Crohn’s disease.
See Also
What is Immunic Inc's Operating Income?
Operating Income
-103.2m
USD
Based on the financial report for Dec 31, 2025, Immunic Inc's Operating Income amounts to -103.2m USD.
What is Immunic Inc's Operating Income growth rate?
Operating Income CAGR 10Y
-7%
Over the last year, the Operating Income growth was -5%. The average annual Operating Income growth rates for Immunic Inc have been -6% over the past three years , -16% over the past five years , and -7% over the past ten years .
